Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ ...Middle East

Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that...

Hence then, the article about sirnaomics doses the first patient in phase i ii clinical study of rnai therapeutic stp705 for treatment of facial squamous cell skin cancer in situ was published today ( Thursday 18/08/2022 - 06:52 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ )

Also on site :

• Ukraine-Russia war latest: Xi reportedly told Trump that Putin might ‘regret’ invading Ukraine
• With Just Two Looks, Taylor Russell Is Already In the Running for Best-Dressed at Cannes
• Un estudio señala que las demoras en Lima durante las elecciones no habrían afectado el resultado en Perú